The Burden of Metastatic Cancer–Induced Bone Pain: A Narrative Review

Autor: Colosia A, Njue A, Bajwa Z, Dragon E, Robinson RL, Sheffield KM, Thakkar S, Richiemer SH

Publikováno v: Journal of Pain Research, Vol Volume 15, Pp 3399-3412 (2022)

Ann Colosia,1 Annete Njue,2 Zahid Bajwa,3 Erika Dragon,4 Rebecca L Robinson,5 Kristin M Sheffield,5 Sheena Thakkar,6 Steven H Richiemer7 1Department of Market Access and Outcomes Strategy, RTI Health Solutions, Research Triangle Park, NC, USA; 2Depar

Externí odkaz: https://doaj.org/article/eb8595bd7a0243a98b142e83e8705beb

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Real-world outcomes in patients with brain metastases secondary to HR+/HER2- MBC treated with abemaciclib and local intracranial therapy.

Autor: Gathirua-Mwangi W; Eli Lilly and Company, Indianapolis, IN, United States., Martin H; Eli Lilly and Company, Indianapolis, IN, United States., He D; Syneos Health, Morrisville, NC, United States., Zheng S; TechData Service Company LLC, King of Prussia, PA, United States., Sheffield KM; Eli Lilly and Company, Indianapolis, IN, United States., John J; Eli Lilly and Company, Indianapolis, IN, United States., Yamazawa E; Harvard Medical School, Massachusetts General Hospital, Boston, MA, United States., Rybowski S; Eli Lilly and Company, Indianapolis, IN, United States., Brastianos PK; Harvard Medical School, Massachusetts General Hospital, Boston, MA, United States.

Publikováno v: The oncologist [Oncologist] 2024 Oct 17. Date of Electronic Publication: 2024 Oct 17.

Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United States.

Autor: Smyth EN; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA., John J; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA., Tiu RV; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA., Willard MD; Eli Lilly and Company, Lilly Global Clinical Development, Indianapolis, IN 46225, USA., Beyrer JK; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA., Bowman L; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA., Sheffield KM; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA., Han Y; Eli Lilly and Company, Statistics RWE, Indianapolis, IN 46225, USA., Brastianos PK; Divisions of Hematology/Oncology and Neuro-Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.

Publikováno v: The oncologist [Oncologist] 2023 Nov 02; Vol. 28 (11), pp. e1075-e1091.

Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.

Autor: Ring A; The Royal Marsden Hospital NHS Foundation Trust, Surrey, SM2 5PT, UK. Alistair.Ring@rmh.nhs.uk., Karuturi M; MD Anderson Cancer Center, Houston, TX, USA., Smyth EN; Eli Lilly and Company, Indianapolis, IN, USA., Lokhandwala T; Xcenda LLC, Carrollton, TX, USA., Sheffield KM; Eli Lilly and Company, Indianapolis, IN, USA., Willey J; Xcenda LLC, Carrollton, TX, USA., Lunacsek O; Xcenda LLC, Carrollton, TX, USA., Sapunar F; Eli Lilly and Company, Lilly House, Basingstoke, Hampshire, UK., Cui ZL; Eli Lilly and Company, Indianapolis, IN, USA., Coutinho A; Xcenda LLC, Carrollton, TX, USA., Rybowski S; Eli Lilly and Company, Indianapolis, IN, USA.

Publikováno v: Advances in therapy [Adv Ther] 2023 May; Vol. 40 (5), pp. 2515-2523. Date of Electronic Publication: 2023 Mar 30.